Xiaomeng Hu has got a master’s degree in pharmaceutics at Huazhong University of Science and Technology in China. Her thesis project is developing the self-adjuvant nanovaccine. Then she spent one and a half years to investigate the applications of exosome in cancer vaccine and treatment for the inflammatory disease at Karolinska Institute in Sweden. After that, Xiaomeng got the opportunity to work on a pharmaceutical project to develop the carrier-free vaccine for personalized treatment at EPFL, supported by the EPFLinnovators programme.
École Polytechnique Fédérale de Lausanne
Content by this speaker
Further Activities to have a look at